Global and United States Metastatic Melanoma Diagnostic Market Report & Forecast 2022-2028

Melanoma is one of the serious types of skin cancers that develops from pigment-containing cells called as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are most common on the back. Moles, brown spots and growths on the skin are found to be the symptoms associated with the disease. When it spreads to other places in body, it's called metastatic, or advanced. Although in many cases metastatic melanoma can’t be cured, treatments and support can help people live longer and better. Doctors have therapies that have greatly increased survival rates. And researchers are working to find new medications that can do even more.
Market Analysis and Insights: Global and United States Metastatic Melanoma Diagnostic Market
This report focuses on global and United States Metastatic Melanoma Diagnostic market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Metastatic Melanoma Diagnostic market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, BRAF Mutation accounting for % of the Metastatic Melanoma Diagnostic global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Pathology Laboratories was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Metastatic Melanoma Diagnostic market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Metastatic Melanoma Diagnostic Scope and Market Size
Metastatic Melanoma Diagnostic market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Metastatic Melanoma Diagnostic market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Metastatic Melanoma Diagnostic market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
BRAF Mutation
Circulating Tumor Cells (CTCs)
Immunohistochemistry
Others
Segment by Application
Pathology Laboratories
Hospitals
Cancer Research Centres
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Myriad Genetics
Abbott Laboratories
Foundation Medicine
Pathway Genomics Corporation
Cancer Genetics
Castle Biosciences
NeoGenomics
Dermtech
Sysmex Inostics